WHERE THERE'S A WILL THERE'S A WEIGH: THE SKINNY ON WEGOVY AND SAXENDA

Katelyn Currier, PharmD

Ellie Rone, PharmD



DISCLOSURES

•Neither presenter has any relevant financial or nonfinancial relationship(s) to disclose



OUTLINE

Overview of GLP-1 RA medications

- Mechanism of action
- Available medications

GLP-1 RA medications for weight loss

- Indications
- Administration
- Dosing
- Effectiveness
- Side effects
- Other considerations

Clinical Pearls

- Cost
- Shortages
- Influence of social media

Summary



OVERVIEW OF GLP-1 RA MEDICATIONS



HOW THEY WORK



Increase insulin secretion after meals → tells the body to move sugar from the bloodstream into cells

> Decrease glucagon secretion after meals → tells the body to keep sugar out of the bloodstream



WHAT MEDICATIONS ARE AVAILABLE



Diabetes

Pramlintide (Symlin®) Dulaglutide (Trulicity®) Exenatide (Bydureon BCise®) Liraglutide (Victoza®) Semaglutide (Ozempic®) Tirzepatide (Mounjaro®)



Weight Loss

Liraglutide (Saxenda®) Semaglutide (Wegovy®)



GLP-1 RA MEDICATIONS FOR WEIGHT LOSS



WHEN SHOULD THESE MEDICATIONS BE CONSIDERED FOR WEIGHT LOSS?

Wegovy

- In addition to reduced-calorie diet and increased physical activity for chronic weight management
- For adults with BMI of ≥30 kg/m² or 27 kg/m² with at least 1 weightrelated condition
- For pediatric patients ≥12 years old with a BMI ≥95th percentile for their age and sex

Saxenda

- In addition to reduced-calorie diet and increased physical activity for chronic weight management
- For adults with BMI of ≥30 kg/m² or 27 kg/m² with at least 1 weightrelated condition
- For pediatric patients ≥12 years old with body weight >60 kg and a BMI of ≥30 kg/m²



HOW ARE THESE MEDICATIONS GIVEN?

	Wegovy	Saxenda
How administered	Injection	Injection
Frequency	Once weekly	Once daily
How often dose can be increased	Every 4 weeks	Every week
How long until maintenance dose is reached	~4 months	~4 weeks



HOW WELL DO THESE MEDICATIONS WORK?

Wegovy

- In trials, patients on the 2.4 mg dose lost an average of ~34 pounds over 17 months (14.9% of total body weight)
- Average waist circumference reduction of ~2.4 inches over a 1-year period

Saxenda

- In trials, patients on the 3 mg dose lost an average of 15 pounds over 17 months (6.4% of total body weight)
- Up to a 21-pound weight loss observed after 1 year when combined with low calorie diet and exercise program



Wilding et al. *N Engl J Med*. 2021;384(11):989-1002. Rubino et al. *JAMA*. 2021;325(14):1414-1425. Rubino et al. *JAMA*. 2022;327(2):138-150. Lundgren et al. *N Engl J Med*. 2021;384(18):1719-1730.

SIDE EFFECTS: SHORT VS LONG TERM

Short Term

- Most common: nausea & vomiting, injection site reaction, diarrhea, constipation, and abdominal pain
- Other commonly reported: headache, fatigue, dyspepsia, dizziness, hypoglycemia (*in patients with type 2 diabetes), flatulence, GERD, and nasopharyngitis

Long term:

• Weight loss

- Semaglutide evidence supports sustained after 3 years with continued dosing
- Saxenda studies indicate, "upon discontinuation of treatment, patients are likely to regain weight"

V

Wegovy[®] [package insert]. Saxenda[®] [package insert].

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide.

PRECAUTIONS & CONTRAINDICATIONS

Contraindications

- History of pancreatitis
- Type 1 diabetes
- Personal/family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B

Precautions

- History of gastrointestinal disease (ex. gastroparesis)
- Renal impairment (*depends* on agent)
- Diabetic retinopathy (in patients with type 2 diabetes)
- Anesthesia

Pregnancy

 ACOG does <u>not</u> recommend medications for weight loss during pregnancy



CLINICAL PEARLS



COST

	Wegovy	Saxenda
Cash Price*	\$1300-1700	\$1300-1700
Available Manufacturer Coupons	 "WeGo Together" Commercial Insurance: max savings/28 days =\$225 Cash: max savings/28 days = \$500 Government: no assistance Savings valid through 12/31/23 	Saxenda Saving Offer was discontinued 6/2023

*Cost depends largely on pharmacy/day/etc.



https://www.novonordisk-us.com/supply-update https://www.novocare.com/obesity/products/saxenda.html https://www.goodrx.com/

SHORTAGES

Wegovy

- Per the manufacturer "<u>demand</u> continues to *outpace* our increasing <u>production</u> of Wegovy" → supply disruption
- Additional manufacturer added 4/2023 to assist in increasing production

Saxenda

• Manufacturer has not provided update; however, it has also been reported to be on shortage

Prescribing for indication

• Diabetes v. Obesity management (right drug for right indication)

Influence of social media

- Celebrity
- TikTok

SUMMARY



SUMMARY

Wegovy and Saxenda are the only GLP-1 RA medications that are <u>FDA-approved</u> for weight loss GLP-1 RA medications help with weight loss by slowing how fast the stomach empties and increasing feelings of fullness

Wegovy and Saxenda are both given via injection: Wegovy once <u>weekly</u>, Saxenda once <u>daily</u> Most common shortterm effects are related to <u>GI upset</u> (N/v, diarrhea, pain and constipation) Cost depends largely <u>on insurance</u> <u>coverage</u>, Wegovy has some assistance available



Questions?





References

- Liraglutide. Lexi-Drugs. Hudson, OH: Lexicomp, 1978-2023. http://online.lexi.com/. Accessed Sept 29, 2023.
- Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
- Semaglutide. Lexi-Drugs. Hudson, OH: Lexicomp, 1978-2023. http://online.lexi.com/. Accessed Sept 29, 2023.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Wegovy[®] [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2023.
- Saxenda[®] [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2022.
- Wadden TA, Hollander P, Klein S, et al.; For NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451.
- Obstetrics & Gynecology 137(6):p e128-e144, June 2021.
- https://www.goodrx.com/
- https://www.novonordisk-us.com/supply-update
- <u>https://www.novocare.com/obesity/products/saxenda.html</u>
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224